The Sea Turtles: China’s Top Pharma Talent Comes Home
The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their…
Address: 22F, N.138 Pudong Avenue
Shanghai 200120 P.R. China ,China
Tel: +86 21 5888 2200
Web: http://www.boehringer-ingelheim.com.cn/
Entering the Chinese market in 1994, Boehringer Ingelheim investment ushered in vigorous development. Boehringer Ingelheim has excellent products in the prescription drugs, consumer self-care medicines and animal health field in the Chinese market and are widely recognized by consumers.
Since 2002, the company has been based in Shanghai. The Zhangjiang Hi-Tech Park factory was built to demonstrate the Boehringer Ingelheim’s determination to further establish itself in China. The Zhangjiang plant has introduced the world’s most advanced pharmaceutical equipment, design and management standards to the country and is comparable to Boehringer Ingelheim plants in any part of the world. The factory operates in strict accordance to international GMP standards. Boehringer Ingelheim’s investment in China amounts $ 29,000,000. The Company has offices in Shanghai, in Beijing, Guangzhou, Shenyang, Chengdu, Nanjing, Hangzhou and has also set up branches in other places, employing a total of more than 2,000 people.
Boehringer Ingelheim’s main business in China includes prescription drugs, consumer self-care medicines and animal health. The business scope encompasses all of the country’s major cities and regions. The company will continue to pursue new drug and disease treatment programs and Boehringer Ingelheim products have gained an excellent reputation in the market, benefitting millions of patients.
Looking ahead, Boehringer Ingelheim Shanghai looks forward to even greater success in the Chinese market, including in the field of human medicine, the company wants to be the key leader in the respiratory, cardiovascular, central nervous system, diabetes and cancer fields. as well as animal health.
With a solid foundation built up over more than a century, Boehringer Ingelheim strives to make greater contributions to Chinese medical and health undertakings.
respiratory, cardiovascular, central nervous system, diabetes, oncology
The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their…
Jin Wang, Partner and Co-leader of the McKinsey China Healthcare Practice, shares the wide-ranging scope of her focus on ‘Big Healthcare’ involving work with healthcare service providers and payers, and pharmaceutical…
China’s healthcare system, which impacts 1.4 billion people, is facing serious capacity issues at all stages of the value chain. Against this backdrop, the country is looking at making wholesale…
Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at…
2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From…
Valtero Canepa, general manager for China of Italian family-owned diagnostic imaging specialist Bracco, outlines the importance of China for the firm, the complexities of operating an international joint venture, and…
White Wang, president of Allergan China, shares the uniqueness of Allergan as a diversified company covering traditional pharmaceuticals and medical aesthetics; the milestones of his first year, with major projects…
Li Qing of Illumina China discusses his recent move to the company, the strategic significance of the China market to Illumina global, and the competitive landscape for next generation sequencing…
Japanese ophthalmology specialist Santen first established a China affiliate in 2005 and has grown very successfully in the past 14 years. GM of Santen Pharmaceutical (China) Co., Ltd. (hereafter, Santen…
China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being…
Kirsch Pharma is a raw materials provider to the pharmaceutical, nutritional, biotechnology, veterinary and cosmetic industries. The business in China was established in 1997, importing high-quality raw materials from Germany.…
Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an…
See our Cookie Privacy Policy Here
